Exosome therapy in Turkey
Exosomes are cell-free vesicles secreted by cells, carrying proteins and RNA that influence how neighbouring cells behave. They are not cells, they do not engraft, and the clinical evidence base is younger and thinner than for MSCs. Türkiye licenses exosome production separately from cell production, which is why it is available here.
Exosomes are not stem cells
The full comparison, including when each is considered, is on the stem cells vs exosomes pillar.
| MSC therapy | Exosome therapy | |
|---|---|---|
| What is given | Living cells | Cell-free vesicles secreted by cells |
| Persistence | Cells are cleared over days to weeks; effects attributed to signalling | No living material; signalling only |
| Storage and handling | Cryopreserved, thawed to a strict window | Generally more stable, easier to ship |
| Evidence base | Hundreds of registered trials, several meta-analyses | Far fewer controlled human trials |
| Regulatory status | Unlicensed for these indications in US/EU/UK | Unlicensed; the US FDA has issued public warnings about unapproved exosome products |
What is exosome therapy and how does it differ from stem cell therapy?
Exosomes are cell-derived vesicles carrying signalling molecules; exosome therapy administers these vesicles rather than living cells. Because no living cells are transferred, handling and storage differ, and the regulatory position differs from cell therapy in most countries. Published human evidence is earlier and thinner than for mesenchymal stem cells, so exosome protocols should be presented as investigational.
Key facts
- What is given
- Cell-derived vesicles, not living cells
- Typical routes
- Intravenous, intra-articular, topical, nebulised
- Evidence stage
- Predominantly early-phase human and preclinical
- Regulatory status
- Varies by country; not an approved therapy in the US or EU for these uses
What we know
- Exosome preparations can be characterised for particle count, size distribution, sterility and endotoxin.
- Preclinical work shows immunomodulatory and pro-repair signalling effects.
What remains uncertain
- Randomised human evidence of clinical benefit is largely absent for the indications marketed online.
- Dose standardisation between providers is poor, so products are not directly comparable.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
What the evidence covers
Most published exosome work is preclinical or early-phase. Human data exist mainly in dermatology, hair, wound healing and musculoskeletal settings, with small samples and short follow-up. Read the current literature directly: exosome clinical trials on PubMed and registered exosome studies on ClinicalTrials.gov.
The FDA public safety notification on exosome products is worth reading before treatment anywhere, including here.
Manufacturing and testing
Exosome preparations are licensed separately in Türkiye and should be released against defined criteria: particle count and size distribution, marker profile, sterility and endotoxin. How products are tested covers the testing vocabulary; ask for the exosome-specific certificate rather than a cell CoA.
Cost and combinations
Exosome programmes are usually less expensive than cultured-cell programmes because there is no cell expansion step. Ranges are on the exosome cost page. Some programmes combine both — see combined stem cell and exosome therapy — which should be justified clinically, not sold as an upgrade.
Frequently asked questions
Is exosome therapy approved anywhere?
No regulator has approved exosome products for the indications discussed here. The FDA has warned specifically about unapproved exosome products marketed to patients.
Is exosome therapy safer than stem cell therapy?
It avoids risks specific to living cells, but "fewer theoretical risks" is not the same as demonstrated safety — the human safety dataset is smaller. Safety pillar.
How soon would any effect be seen?
Reported timelines vary widely by indication and are drawn largely from small uncontrolled series. Safety and timeline page.
Read next
Have your records reviewed first
Whether any of this applies to you can only be decided after a physician reviews your medical records. The review is free and there is no obligation to travel.
Request a free medical review